← Back to Search

11C-BMS-986196 for Multiple Sclerosis

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Study Summary

This trialevaluates the safety, tolerability, and effects of a drug for multiple sclerosis patients after IV injection.

Who is the study for?
This trial is for adults with a BMI of 18-34 kg/m2 and weight ≥50 kg. Healthy participants are needed, as well as those diagnosed with MS per the McDonald criteria, having an EDSS score of 0-6.5. People can't join if they've had recent surgery or have benign MS, spinal MS without brain lesions, or any significant illness.Check my eligibility
What is being tested?
The study tests the safety and body distribution of a substance called 11C-BMS-986196 given through IV to healthy people and those with multiple sclerosis (MS). It looks at how the body processes this substance and its effects on the central nervous system.See study design
What are the potential side effects?
While specific side effects aren't listed here, generally such studies monitor for reactions at injection sites, changes in vital signs like blood pressure or heart rate, allergic reactions, headaches or dizziness.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Image acquisition window after administration of 11C-BMS-986196
Incidence of Serious TEAEs
Incidence of TEAEs by Maximum Severity
+7 more
Secondary outcome measures
Calculated SUV in the brain
Calculated VT in the brain

Trial Design

2Treatment groups
Experimental Treatment
Group I: Part B - Participants with MSExperimental Treatment1 Intervention
Group II: Part A - Healthy ParticipantsExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
11C-BMS-986196
2021
Completed Phase 1
~10

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,636 Previous Clinical Trials
4,127,554 Total Patients Enrolled
13 Trials studying Multiple Sclerosis
22,270 Patients Enrolled for Multiple Sclerosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis
2021. "A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05064436.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top